Doctors are finally learning to manage antidepressant withdrawal

Mark Horowitz, an overworked medical school student, began taking an antidepressant 20 years ago to alleviate his anxiety about his future. Escitalopram, the pill he took, proved effective, and he continued to use it for a decade without much thought, until he decided to stop after reading an article suggesting the effects of antidepressants tend to fade over time.

Tapering his dose over several months, Horowitz experienced a dramatic worsening of his symptoms, including panic attacks, terror, dizziness, and insomnia. He found the withdrawal symptoms far worse than the depression that initially led him to start taking the medication.

Horowitz is not alone in his experience. As more people speak out about the challenges of reducing or stopping their antidepressant doses, questions arise about the safety and reliance on these medications. Growing research supports Horowitz's account, leading to a shift in how we treat depression.

Since their approval for medical use nearly four decades ago, SSRIs have become prevalent. Over 16% of people in the US, 15% in the UK, and 14% in Australia now take antidepressants, with SSRIs being the majority. These medications were more popular than earlier antidepressants due to their safety and minimal side effects. While SSRIs have benefits, some psychiatrists argue that their risks have been downplayed.

Clinicians and patients have not closely monitored their use, resulting in widespread long-term prescribing without guidance on tapering doses or managing withdrawal symptoms.

A 2022 study found that none of the clinical practice guidelines provided clear instructions on how to manage dose reduction or withdrawal symptoms, leaving patients and physicians unaware of these essential aspects. As a result, many continue to use SSRIs for extended periods, often exceeding five years on average in the US, with some taking the medication for a decade or more. However, the long-term effects and safety of such prolonged use remain poorly understood.

Horowitz's experience aligns with this growing body of evidence. His self-reported withdrawal symptoms, such as insomnia, panic attacks, and a feeling of living in a dream, were not features of his original depression. Research now validates his account, indicating that the intensity and severity of withdrawal symptoms can be extreme when individuals cease SSRIs.

Misinterpretations of these symptoms as a recurrence of depression can lead to unnecessary reinstatement of the drug or dose escalation, perpetuating the cycle of antidepressant use.